Literature DB >> 16820636

Long-term outcomes after valve replacement for low-gradient aortic stenosis: impact of prosthesis-patient mismatch.

Alexander Kulik1, Ian G Burwash, Varun Kapila, Thierry G Mesana, Marc Ruel.   

Abstract

BACKGROUND: The long-term outcomes of patients with low-gradient aortic stenosis (LGAS) after aortic valve replacement (AVR) are poorly defined. The purpose of this study was to define the long-term outcomes of LGAS patients after AVR and to evaluate the potential impact of prosthesis-patient mismatch (PPM) in these patients. METHODS AND
RESULTS: A cohort of 664 patients undergoing AVR for aortic stenosis after 1990 were followed-up prospectively with annual clinical assessment and echocardiography (total follow-up 3447 patient-years; mean follow-up 5.2+/-3.3 years). LGAS was defined as an aortic valve area <1.2 cm2, a mean transvalvular pressure gradient <40 mm Hg, and a left ventricular (LV) ejection fraction <50%, and was present in 79 patients. Rates and correlates of survival, freedom from congestive heart failure (CHF), and LV mass regression after AVR were determined using multivariate regression methods. Ten-year survival and freedom from CHF after AVR were 72.7+/-7.5% and 68.2+/-9.5%, respectively, for patients with LGAS, compared with 89.6+/-1.8% and 84.1+/-4.2% for patients without LGAS (hazard ratio [HR] for death and postoperative CHF, 3.1+/-1.1 and 2.7+/-0.9, respectively; P<0.01). In LGAS patients, PPM, defined as an indexed effective orifice area < or = 0.85 cm2/m2, was independently associated with increased rates of CHF (HR, 3.6+/-2.2; P=0.039), impaired LV mass regression (P=0.037), and a trend toward increased late mortality (HR, 3.0+/-1.9; P=0.084).
CONCLUSIONS: Patients with LGAS have worse long-term outcomes after AVR compared with patients without LGAS. PPM adversely affects the long-term outcomes of LGAS patients and should be avoided in this population.

Entities:  

Mesh:

Year:  2006        PMID: 16820636     DOI: 10.1161/CIRCULATIONAHA.105.001180

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

1.  Prevention of valve prosthesis--patient mismatch before aortic valve replacement: does it matter and is it feasible?

Authors:  Philippe Pibarot; Jean G Dumesnil
Journal:  Heart       Date:  2007-05       Impact factor: 5.994

2.  Patterns of left ventricular remodeling in aortic stenosis: therapeutic implications.

Authors:  Sammy Elmariah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-07

Review 3.  Echocardiographic Evaluation of Aortic Stenosis - Normal Flow and Low Flow Scenarios.

Authors:  Ian G Burwash
Journal:  Eur Cardiol       Date:  2014-12

Review 4.  Low-flow, low-gradient, normal ejection fraction aortic stenosis.

Authors:  Philippe Pibarot; Jean G Dumesnil
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

5.  Low gradient aortic stenosis.

Authors:  Katie M Doucet; Ian G Burwash
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-05

Review 6.  Low-gradient aortic stenosis.

Authors:  Marie-Annick Clavel; Julien Magne; Philippe Pibarot
Journal:  Eur Heart J       Date:  2016-03-31       Impact factor: 29.983

7.  Pulmonary hypertension in cardiac surgery.

Authors:  André Denault; Alain Deschamps; Jean-Claude Tardif; Jean Lambert; Louis Perrault
Journal:  Curr Cardiol Rev       Date:  2010-02

Review 8.  Transcatheter aortic valve implantation in the elderly: who to refer?

Authors:  Matthew Finn; Philip Green
Journal:  Prog Cardiovasc Dis       Date:  2014-08-12       Impact factor: 8.194

Review 9.  Prosthesis-Patient Mismatch After Aortic Valve Replacement.

Authors:  Abdellaziz Dahou; Haïfa Mahjoub; Philippe Pibarot
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-11

Review 10.  New concepts in valvular hemodynamics: implications for diagnosis and treatment of aortic stenosis.

Authors:  Philippe Pibarot; Jean G Dumesnil
Journal:  Can J Cardiol       Date:  2007-10       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.